LitAlert ~~ GeneLit.com

    • Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    • Fedier A, Maggi N, Tozzi A, Disler M, Coelho R, Jacob F, Heinzelmann-Schwarz V.
    • Int J Oncol. 2022 Jul;61(1):89. doi: 10.3892/ijo.2022.5379. Epub 2022 Jun 1.
    • The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.
    • Hoxhaj A, Drissen MMCM, Vos JR, Bult P, Mann RM, Hoogerbrugge N.
    • Cancer. 2022 Jun 1. doi: 10.1002/cncr.34326. Epub ahead of print
    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
    • Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK.
    • BMC Med Genomics. 2022 May 31;15(1):122. doi: 10.1186/s12920-022-01270-4.
    • Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    • Minoura Y, Takahashi M, Maeda H, Kuwahara S, Tachikawa H, Yamamoto M, Tomioka N, Watanabe K, Sakurai A.
    • Breast Cancer. 2022 May 31. doi: 10.1007/s12282-022-01360-2. Epub ahead of print.
    • CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset.
    • Avesani G, Tran HE, Cammarata G, Botta F, Raimondi S, Russo L, Persiani S, Bonatti M, Tagliaferri T, Dolciami M, Celli V, Boldrini L, Lenkowicz J, Pricolo P, Tomao F, Rizzo SMR, Colombo N, Manganaro L, Fagotti A, Scambia G, Gui B, Manfredi R.
    • Cancers (Basel). 2022 May 31;14(11):2739. doi: 10.3390/cancers14112739.
    • Parp Inhibition and Beyond in Brca- Associated Breast Cancer in Women: A State- Of- The- Art Summary of (Pre) - Clinical Research into Risk Reduction and Clinical Benefits.
    • Pauwels EKJ, Bourguignon MH.
    • Med Princ Pract. 2022 May 30. doi: 10.1159/000525281. Epub ahead of print.
    • Is there a "Low Risk" Patient Population in Advanced Epithelial Ovarian Cancer?: A Critical Analysis.
    • Chambers LM, O'Malley DM, Coleman RL, Herzog TJ.
    • Am J Obstet Gynecol. 2022 May 28:S0002-9378(22)00412-4. doi: 10.1016/j.ajog.2022.05.047. Epub ahead of print.
    • Commentary
    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • CHEK2 variants: linking functional impact to cancer risk.
    • Boonen RACM, Vreeswijk MPG, van Attikum H.
    • Trends Cancer. 2022 May 25:S2405-8033(22)00096-6. doi: 10.1016/j.trecan.2022.04.009. Epub ahead of print.
    • Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer.
    • Vargas E, de Deugd R, Villegas VE, Gil F, Mora L, Viaña LF, Bruges R, Gonzalez A, Galvis JC, Hamann U, Torres D.
    • Oncologist. 2022 Mar 4;27(2):e151-e157. doi: 10.1093/oncolo/oyab026.
    • Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
    • Heise M, Jarzemski P, Nowak D, Bak A, Junkiert-Czarnecka A, Pilarska-Deltow M, Borysiak M, Pilarska B, Haus O.
    • Cancer Control. 2022 Jan-Dec;29:10732748211062342. doi: 10.1177/10732748211062342.